19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end ...
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...
19, 2024 — Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end ...
Reminiscence refers to the act of recalling memories from the past. It is a familiar activity to everyone, but reminiscence can be highly beneficial for people with Alzheimer’s disease. It can support ...